Acute and long-term neurological manifestations of Covid-19: insights from virology and neurology
Views: 24DOI:
https://doi.org/10.48208/HeadacheMed.2025.2Keywords:
Neuro-Covid, SARS-CoV-2, Neurological manifestations, Long Covid, NeuroinvasionAbstract
Introduction
This literature review examines the profound impact of Covid-19, caused by SARS-CoV-2, on the nervous system. While the virus is predominantly associated with respiratory complications, emerging evidence highlights its strong neurotropic potential, leading to a broad spectrum of neurological disorders. This review explores the convergence of virology and neurology, emphasizing both acute and long-term neurological consequences of the disease.
Methods
A systematic review following PRISMA guidelines was conducted using databases such as PubMed, Scopus, and Web of Science. Studies were selected based on their relevance to the pathophysiology, clinical presentations, and prolonged neurological effects of Covid-19. Preference was given to peer-reviewed research, including meta-analyses and clinical case reports published between 2020 and 2024.
Results
The review identifies various pathways through which SARS-CoV-2 affects the nervous system, including direct neuroinvasion and systemic inflammatory responses. Acute neurological conditions such as encephalitis, stroke, and Guillain-Barré syndrome have been frequently reported, while chronic complications include cognitive dysfunction, neurodegenerative disorders, and psychiatric disturbances. These findings highlight the intricate and enduring neurological burden of Covid-19.
Conclusion
Neuro-Covid presents an ongoing challenge in the post-pandemic landscape. A deeper understanding of its neurological implications is essential for enhancing patient management and shaping future research directions. This review highlights the importance of increased clinical vigilance and a multidisciplinary strategy to effectively address the complex and evolving spectrum of Covid-19-related neurological disorders.
Downloads
References
Yu H, Sun T, Feng J. Complications and Pathophysiology of COVID-19 in the Nervous System. Front Neurol 2020;11. Doi:10.3389/fneur.2020.573421. DOI: https://doi.org/10.3389/fneur.2020.573421
Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. New England Journal of Medicine 2020;382. Doi:10.1056/NEJMc2009787. DOI: https://doi.org/10.1056/NEJMc2009787
Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020;7:875–82. Doi:10.1016/S2215-0366(20)30287-X. DOI: https://doi.org/10.2139/ssrn.3601761
Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2021;24:168–75. Doi:10.1038/s41593-020-00758-5. DOI: https://doi.org/10.1038/s41593-020-00758-5
Paniz‐Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). J Med Virol 2020;92:699–702. Doi:10.1002/jmv.25915. DOI: https://doi.org/10.1002/jmv.25915
Kabbani N, Olds JL. Does COVID19 Infect the Brain? If So, Smokers Might Be at a Higher Risk. Mol Pharmacol 2020;97:351–3. Doi:10.1124/molpharm.120.000014. DOI: https://doi.org/10.1124/molpharm.120.000014
Nath A. Neurologic complications of coronavirus infections. Neurology 2020;94:809–10. Doi:10.1212/WNL.0000000000009455. DOI: https://doi.org/10.1212/WNL.0000000000009455
Baig AM. Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers. J Med Virol 2021;93:2555–6. Doi:10.1002/jmv.26624. DOI: https://doi.org/10.1002/jmv.26624
Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020;5:279–84. Doi:10.1136/svn-2020-000431. DOI: https://doi.org/10.1136/svn-2020-000431
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683. Doi:10.1001/jamaneurol.2020.1127. DOI: https://doi.org/10.1001/jamaneurol.2020.1127
Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020;143:3104–20. Doi:10.1093/brain/awaa240. DOI: https://doi.org/10.1093/brain/awaa240
Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle Nerve 2020;62:485–91. Doi:10.1002/mus.27024. DOI: https://doi.org/10.1002/mus.27024
Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain 2021;144:682–93. Doi:10.1093/brain/awaa433. DOI: https://doi.org/10.1093/brain/awaa433
Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study. Clinical Infectious Diseases 2020;71:889–90. Doi:10.1093/cid/ciaa330. DOI: https://doi.org/10.1093/cid/ciaa330
Gómez-Melero S, Caballero-Villarraso J, Escribano BM, Galvao-Carmona A, Túnez I, Agüera-Morales E. Impact of Cognitive Impairment on Quality of Life in Multiple Sclerosis Patients—A Comprehensive Review. J Clin Med 2024;13:3321. Doi:10.3390/jcm13113321. DOI: https://doi.org/10.3390/jcm13113321
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019. JAMA Neurol 2020;77:1018. Doi:10.1001/jamaneurol.2020.2065. DOI: https://doi.org/10.1001/jamaneurol.2020.2065
Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021;27:626–31. Doi:10.1038/s41591-021-01292-y. DOI: https://doi.org/10.1038/s41591-021-01292-y
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 2020;12:69. Doi:10.1186/s13195-020-00640-3. DOI: https://doi.org/10.1186/s13195-020-00640-3
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021;8:416–27. Doi:10.1016/S2215-0366(21)00084-5. DOI: https://doi.org/10.1016/S2215-0366(21)00084-5
Holder K, Reddy PH. The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. The Neuroscientist 2021;27:331–9. Doi:10.1177/1073858420960443. DOI: https://doi.org/10.1177/1073858420960443
Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, et al. Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Immunohorizons 2020;4:201–15. Doi:10.4049/immunohorizons.2000006. DOI: https://doi.org/10.4049/immunohorizons.2000006
Sher EK, Ćosović A, Džidić-Krivić A, Farhat EK, Pinjić E, Sher F. Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Life Sci 2023;319:121531. Doi:10.1016/j.lfs.2023.121531. DOI: https://doi.org/10.1016/j.lfs.2023.121531
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci 2020;11:995–8. Doi:10.1021/acschemneuro.0c00122. DOI: https://doi.org/10.1021/acschemneuro.0c00122
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020;73:807–16. Doi:10.1016/j.jhep.2020.05.002. DOI: https://doi.org/10.1016/j.jhep.2020.05.002
Santos MO, Gonçalves LC, Silva PAN, Moreira ALE, Ito CRM, Peixoto FAO, et al. Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes. J Pediatr (Rio J) 2022;98:338–49. Doi:10.1016/j.jped.2021.08.006. DOI: https://doi.org/10.1016/j.jped.2021.08.006
LaRovere KL, Riggs BJ, Poussaint TY, Young CC, Newhams MM, Maamari M, et al. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome. JAMA Neurol 2021;78:536. Doi:10.1001/jamaneurol.2021.0504. DOI: https://doi.org/10.1001/jamaneurol.2021.0504
Morand A, Urbina D, Fabre A. COVID-19 and Kawasaki Like Disease: The Known-Known, the Unknown-Known and the Unknown-Unknown 2020. Doi:10.20944/preprints202005.0160.v1. DOI: https://doi.org/10.20944/preprints202005.0160.v1
Nalbandian A, Sehgal K, Gupta A, Madhavan M V., McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601–15. Doi:10.1038/s41591-021-01283-z. DOI: https://doi.org/10.1038/s41591-021-01283-z
Avittan H, Kustovs D. Cognition and Mental Health in Pediatric Patients Following COVID-19. Int J Environ Res Public Health 2023;20:5061. Doi:10.3390/ijerph20065061. DOI: https://doi.org/10.3390/ijerph20065061
Sharma VK, Singh TG, Mehta V, Mannan A. Biomarkers: Role and Scope in Neurological Disorders. Neurochem Res 2023;48:2029–58. Doi:10.1007/s11064-023-03873-4. DOI: https://doi.org/10.1007/s11064-023-03873-4
Kanberg N, Simrén J, Edén A, Andersson L-M, Nilsson S, Ashton NJ, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 2021;70:103512. Doi:10.1016/j.ebiom.2021.103512. DOI: https://doi.org/10.1016/j.ebiom.2021.103512
Paterson RW, Benjamin LA, Mehta PR, Brown RL, Athauda D, Ashton NJ, et al. Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Commun 2021;3. Doi:10.1093/braincomms/fcab099. DOI: https://doi.org/10.1093/braincomms/fcab219
Barbosa-Silva MC, Lima MN, Battaglini D, Robba C, Pelosi P, Rocco PRM, et al. Infectious disease-associated encephalopathies. Crit Care 2021;25:236. Doi:10.1186/s13054-021-03659-6. DOI: https://doi.org/10.1186/s13054-021-03659-6
Kiani L. Preventing COVID-19 neurological complications. Nat Rev Neurol 2022;18:699–699. Doi:10.1038/s41582-022-00744-4. DOI: https://doi.org/10.1038/s41582-022-00744-4
Rolin S, Chakales A, Verduzco-Gutierrez M. Rehabilitation Strategies for Cognitive and Neuropsychiatric Manifestations of COVID-19. Curr Phys Med Rehabil Rep 2022;10:182–7. Doi:10.1007/s40141-022-00352-9. DOI: https://doi.org/10.1007/s40141-022-00352-9
Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. Journal of Alzheimer’s Disease 2020;76:3–19. Doi:10.3233/JAD-200581. DOI: https://doi.org/10.3233/JAD-200581
Thankachen SS, Devasenapathy N, Bassi A, Ghosh A, Arfin S, Gummidi B, et al. Colchicine to reduce coronavirus disease-19-related inflammation and cardiovascular complications in high-risk patients post-acute infection with SARS-COV-2—a study protocol for a randomized controlled trial. Trials 2024;25:378. Doi:10.1186/s13063-024-08205-7. DOI: https://doi.org/10.1186/s13063-024-08205-7
Daniels K, Mourad J, Bonnechère B. Exploring the Use of Mobile Health for the Rehabilitation of Long COVID Patients: A Scoping Review. Healthcare 2024;12:451. Doi:10.3390/healthcare12040451. DOI: https://doi.org/10.3390/healthcare12040451
D’Arcy RCN, Sandhu JK, Marshall S, Besemann M. Mitigating Long-Term COVID-19 Consequences on Brain Health. Front Neurol 2021;12. Doi:10.3389/fneur.2021.630986. DOI: https://doi.org/10.3389/fneur.2021.630986
Frank MG, Ball JB, Hopkins S, Kelley T, Kuzma AJ, Thompson RS, et al. SARS-CoV-2 S1 subunit produces a protracted priming of the neuroinflammatory, physiological, and behavioral responses to a remote immune challenge: A role for corticosteroids. Brain Behav Immun 2024;121:87–103. Doi:10.1016/j.bbi.2024.07.034. DOI: https://doi.org/10.1016/j.bbi.2024.07.034
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kirolos Eskandar (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
